Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281957 · ClinicalTrials.gov registry record · Phase 2
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT00281957: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00281957 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00281957, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery. Sorafenib, temsirolimus, and tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib and tipifarnib may also stop the growth of tumor by blocking blood flow to the tumor. It is not yet known whether sorafenib is more effective when given together with temsirolimus or tipifarnib in treating patients with malignant melanoma.
Interventions
- DRUG sorafenib tosylate
- DRUG tipifarnib
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00281957
The ClinicalTrials.gov registry entry for NCT00281957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sorafenib tosylate is the first listed.
NCT00281957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00281957 about?
NCT00281957 is a clinical study titled "Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery". This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery. Sorafenib, temsirolimus, and tipifarnib may stop the growth of tumor cells by blocking some of the...
What is the current status of trial NCT00281957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2007-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00281957?
The interventions under investigation include: sorafenib tosylate (DRUG), tipifarnib (DRUG), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00281957?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.